Monday, December 12, 2011
Enzon Pharmaceuticals Inc., of Piscataway, N.J., presented Phase II data showing PEG-SN38 (EZN-2208) demonstrated activity in patients with previously treated metastatic breast cancer. Overall response was 21 percent in patients previously treated with anthracycline and taxane (AT) and 11 percent in patients previously treated with anthracycline, taxane and capecitabine (ATX).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.